1
|
Spry JA, Siegel B, Bakermans C, Beaty DW, Bell MS, Benardini JN, Bonaccorsi R, Castro-Wallace SL, Coil DA, Coustenis A, Doran PT, Fenton L, Fidler DP, Glass B, Hoffman SJ, Karouia F, Levine JS, Lupisella ML, Martin-Torres J, Mogul R, Olsson-Francis K, Ortega-Ugalde S, Patel MR, Pearce DA, Race MS, Regberg AB, Rettberg P, Rummel JD, Sato KY, Schuerger AC, Sefton-Nash E, Sharkey M, Singh NK, Sinibaldi S, Stabekis P, Stoker CR, Venkateswaran KJ, Zimmerman RR, Zorzano-Mier MP. Planetary Protection Knowledge Gap Closure Enabling Crewed Missions to Mars. Astrobiology 2024; 24:230-274. [PMID: 38507695 DOI: 10.1089/ast.2023.0092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/22/2024]
Abstract
As focus for exploration of Mars transitions from current robotic explorers to development of crewed missions, it remains important to protect the integrity of scientific investigations at Mars, as well as protect the Earth's biosphere from any potential harmful effects from returned martian material. This is the discipline of planetary protection, and the Committee on Space Research (COSPAR) maintains the consensus international policy and guidelines on how this is implemented. Based on National Aeronautics and Space Administration (NASA) and European Space Agency (ESA) studies that began in 2001, COSPAR adopted principles and guidelines for human missions to Mars in 2008. At that point, it was clear that to move from those qualitative provisions, a great deal of work and interaction with spacecraft designers would be necessary to generate meaningful quantitative recommendations that could embody the intent of the Outer Space Treaty (Article IX) in the design of such missions. Beginning in 2016, COSPAR then sponsored a multiyear interdisciplinary meeting series to address planetary protection "knowledge gaps" (KGs) with the intent of adapting and extending the current robotic mission-focused Planetary Protection Policy to support the design and implementation of crewed and hybrid exploration missions. This article describes the outcome of the interdisciplinary COSPAR meeting series, to describe and address these KGs, as well as identify potential paths to gap closure. It includes the background scientific basis for each topic area and knowledge updates since the meeting series ended. In particular, credible solutions for KG closure are described for the three topic areas of (1) microbial monitoring of spacecraft and crew health; (2) natural transport (and survival) of terrestrial microbial contamination at Mars, and (3) the technology and operation of spacecraft systems for contamination control. The article includes a KG data table on these topic areas, which is intended to be a point of departure for making future progress in developing an end-to-end planetary protection requirements implementation solution for a crewed mission to Mars. Overall, the workshop series has provided evidence of the feasibility of planetary protection implementation for a crewed Mars mission, given (1) the establishment of needed zoning, emission, transport, and survival parameters for terrestrial biological contamination and (2) the creation of an accepted risk-based compliance approach for adoption by spacefaring actors including national space agencies and commercial/nongovernment organizations.
Collapse
Affiliation(s)
| | | | - Corien Bakermans
- Department of Biology, Penn. State University (Altoona), Altoona, Pennsylvania, USA
| | - David W Beaty
- Jet Propulsion Laboratory/California Institute of Technology, Pasadena, California, USA
| | | | | | - Rosalba Bonaccorsi
- SETI Institute, Mountain View, California, USA
- NASA Ames Research Center, Moffett Field, California, USA
| | | | - David A Coil
- School of Medicine, University of California, Davis, Davis, California, USA
| | | | - Peter T Doran
- Department of Geology & Geophysics, Louisiana State University, Baton Rouge, Louisiana, USA
| | - Lori Fenton
- SETI Institute, Mountain View, California, USA
| | - David P Fidler
- Council on Foreign Relations, Washington, District of Columbia, USA
| | - Brian Glass
- NASA Ames Research Center, Moffett Field, California, USA
| | | | - Fathi Karouia
- NASA Ames Research Center, Moffett Field, California, USA
| | - Joel S Levine
- College of William & Mary, Williamsburg, Virginia, USA
| | | | - Javier Martin-Torres
- School of Geoscience, University of Aberdeen, Aberdeen, United Kingdom
- Instituto Andaluz de Ciencias de la Tierra (CSIC-UGR), Armilla, Spain
| | - Rakesh Mogul
- California Polytechnic (Pomona), Pomona, California, USA
| | - Karen Olsson-Francis
- School of Environment, Earth and Ecosystem Sciences, Open University, Milton Keynes, United Kingdom
| | | | - Manish R Patel
- School of Environment, Earth and Ecosystem Sciences, Open University, Milton Keynes, United Kingdom
| | - David A Pearce
- Department of Applied Sciences, Northumbria University, Newcastle Upon Tyne, United Kingdom
| | | | | | | | - John D Rummel
- Friday Harbor Associates LLC, Friday Harbor, Washington, USA
| | | | - Andrew C Schuerger
- Department of Plant Pathology, University of Florida, Merritt Island, Florida, USA
| | | | - Matthew Sharkey
- US Department of Health & Human Services, Washington, District of Columbia, USA
| | - Nitin K Singh
- Jet Propulsion Laboratory/California Institute of Technology, Pasadena, California, USA
| | | | | | - Carol R Stoker
- NASA Ames Research Center, Moffett Field, California, USA
| | | | | | | |
Collapse
|
2
|
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard JE, Kröger N, Blaise D, Peffault de Latour R, Kulagin A, Mousavi A, Stelljes M, Hamladji RM, Middeke JM, Salmenniemi U, Sengeloev H, Forcade E, Platzbecker U, Reményi P, Angelucci E, Chevallier P, Yakoub-Agha I, Craddock C, Ciceri F, Schroeder T, Aljurf M, Ch K, Moiseev I, Penack O, Schoemans H, Mohty M, Glass B, Sureda A, Basak G, Peric Z. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study. Bone Marrow Transplant 2024; 59:232-238. [PMID: 38007531 DOI: 10.1038/s41409-023-02147-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 10/04/2023] [Accepted: 11/03/2023] [Indexed: 11/27/2023]
Abstract
Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT registry who underwent alloHCT between 2010 and 2019 for oncohaematological disease. Our primary objective was to develop a new prognostic score for overall mortality (OM), with a secondary objective of predicting non-relapse mortality (NRM) using the OM score. AI techniques were employed. The model for OM was trained, optimized, and validated using 70%, 15%, and 15% of the data set, respectively. The top models, "gradient boosting" for OM (AUC = 0.64) and "elasticnet" for NRM (AUC = 0.62), were selected. The analysis included 33,927 patients. In the final prognostic model, patients with the lowest score had a 2-year OM and NRM of 18 and 13%, respectively, while those with the highest score had a 2-year OM and NRM of 82 and 93%, respectively. The results were consistent in the subset of the haploidentical cohort (n = 4386). Our score effectively stratifies the risk of OM and NRM in the current era but do not significantly improve mortality prediction. Future prognostic scores can benefit from identifying biological or dynamic markers post alloHCT.
Collapse
Affiliation(s)
- A Mussetti
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - B Rius-Sansalvador
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - V Moreno
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Peczynski
- EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM Unité Mixte de Recherche (UMR)-S 938, Sorbonne University, Paris, France
| | - E Polge
- EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukaemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France
| | | | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Blaise
- Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
| | - R Peffault de Latour
- Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Université Paris Diderot, Institut Universitaire d'Hématologie, Sorbonne Paris Cité, Paris, France
| | - A Kulagin
- Raisa Memorial (RM) Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | - A Mousavi
- Shariati Hospital, Haematology-Oncology and BMT Research, Tehran, Islamic Republic of Iran
| | - M Stelljes
- Department of Medicine A, University Hospital Münster, Münster, Germany
| | - R M Hamladji
- Centre Pierre et Marie Curie, Service Hématologie Greffe de Moëlle, Alger, Algeria
| | - J M Middeke
- Med. Klinik I, University Hospital, TU Dresden, Germany
| | - U Salmenniemi
- HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - H Sengeloev
- Bone Marrow Transplant Unit Copenhagen, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - E Forcade
- CHU Bordeaux, Service d'hématologie Clinique et Thérapie Cellulaire, 33000, Pessac, France
| | | | - P Reményi
- Department of Haematology and Stem Cell Transplant, Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary
| | - E Angelucci
- Haematology and Cellular Therapy Unit. IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | | | - I Yakoub-Agha
- CHU de Lille LIRIC, INSERM U995, Université de Lille, Lille, France
| | - C Craddock
- Department of Haematology, University Hospital Birmingham NHS Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK
| | - F Ciceri
- Haematology & Bone Marrow Transplant, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - T Schroeder
- Department of Bone Marrow Transplantation, University Hospital, Essen, Germany
| | - M Aljurf
- Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | | | - I Moiseev
- R.M.Gorbacheva Memorial Institute of Oncology, Haematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation
| | - O Penack
- Department of Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - H Schoemans
- Department of Haematology, University Hospitals Leuven, Leuven, Belgium
- Department of Public Health and Primary Care, ACCENT VV, KU Leuven - University of Leuven, Leuven, Belgium
| | - M Mohty
- Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
| | - B Glass
- Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - A Sureda
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
| | - G Basak
- Department of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Z Peric
- School of medicine, University of Zagreb and University Hospital Centre Zagreb, Zagreb, Croatia
| |
Collapse
|
3
|
Moreno-Paz M, dos Santos Severino RS, Sánchez-García L, Manchado JM, García-Villadangos M, Aguirre J, Fernández-Martínez MA, Carrizo D, Kobayashi L, Dave A, Warren-Rhodes K, Davila A, Stoker CR, Glass B, Parro V. Life Detection and Microbial Biomarker Profiling with Signs of Life Detector-Life Detector Chip During a Mars Drilling Simulation Campaign in the Hyperarid Core of the Atacama Desert. Astrobiology 2023; 23:1259-1283. [PMID: 37930382 PMCID: PMC10825288 DOI: 10.1089/ast.2021.0174] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 07/02/2023] [Indexed: 11/07/2023]
Abstract
The low organic matter content in the hyperarid core of the Atacama Desert, together with abrupt temperature shifts and high ultraviolet radiation at its surface, makes this region one of the best terrestrial analogs of Mars and one of the best scenarios for testing instrumentation devoted to in situ planetary exploration. We have operated remotely and autonomously the SOLID-LDChip (Signs of Life Detector-Life Detector Chip), an antibody microarray-based sensor instrument, as part of a rover payload during the 2019 NASA Atacama Rover Astrobiology Drilling Studies (ARADS) Mars drilling simulation campaign. A robotic arm collected drilled cuttings down to 80 cm depth and loaded SOLID to process and assay them with LDChip for searching for molecular biomarkers. A remote science team received and analyzed telemetry data and LDChip results. The data revealed the presence of microbial markers from Proteobacteria, Acidobacteria, Bacteroidetes, Actinobacteria, Firmicutes, and Cyanobacteria to be relatively more abundant in the middle layer (40-50 cm). In addition, the detection of several proteins from nitrogen metabolism indicates a pivotal role in the system. These findings were corroborated and complemented on "returned samples" to the lab by a comprehensive analysis that included DNA sequencing, metaproteomics, and a metabolic reconstruction of the sampled area. Altogether, the results describe a relatively complex microbial community with members capable of nitrogen fixation and denitrification, sulfur oxidation and reduction, or triggering oxidative stress responses, among other traits. This remote operation demonstrated the high maturity of SOLID-LDChip as a powerful tool for remote in situ life detection for future missions in the Solar System.
Collapse
Affiliation(s)
- Mercedes Moreno-Paz
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
| | - Rita Sofia dos Santos Severino
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
- Departament of Física y Matemáticas y de Automática, University of Alcalá de Henares (UAH), Madrid, Spain
| | - Laura Sánchez-García
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
| | - Juan Manuel Manchado
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
| | | | - Jacobo Aguirre
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
| | - Miguel Angel Fernández-Martínez
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
- Department of Natural Resource Sciences, McGill University, Québec, Canada
| | - Daniel Carrizo
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
| | - Linda Kobayashi
- Space Science Division and Astrobiology Division, NASA Ames Research Center, Moffett Field, California, USA
| | - Arwen Dave
- Space Science Division and Astrobiology Division, NASA Ames Research Center, Moffett Field, California, USA
| | - Kim Warren-Rhodes
- Space Science Division and Astrobiology Division, NASA Ames Research Center, Moffett Field, California, USA
- Carl Sagan Center, SETI Institute, Mountain View, California, USA
| | - Alfonso Davila
- Space Science Division and Astrobiology Division, NASA Ames Research Center, Moffett Field, California, USA
| | - Carol R. Stoker
- Space Science Division and Astrobiology Division, NASA Ames Research Center, Moffett Field, California, USA
| | - Brian Glass
- Space Science Division and Astrobiology Division, NASA Ames Research Center, Moffett Field, California, USA
| | - Víctor Parro
- Department of Molecular Evolution, Centro de Astrobiología (CAB), INTA-CSIC, Madrid, Spain
| |
Collapse
|
4
|
Bonaccorsi R, Glass B, Moreno-Paz M, García-Villadangos M, Warren-Rhodes K, Parro V, Manchado JM, Wilhelm MB, McKay CP. In Situ Real-Time Monitoring for Aseptic Drilling: Lessons Learned from the Atacama Rover Astrobiology Drilling Studies Contamination Control Strategy and Implementation and Application to the Icebreaker Mars Life Detection Mission. Astrobiology 2023; 23:1303-1336. [PMID: 38133823 DOI: 10.1089/ast.2022.0133] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
In 2019, the Atacama Rover Astrobiology Drilling Studies (ARADS) project field-tested an autonomous rover-mounted robotic drill prototype for a 6-Sol life detection mission to Mars (Icebreaker). ARADS drilled Mars-like materials in the Atacama Desert (Chile), one of the most life-diminished regions on Earth, where mitigating contamination transfer into life-detection instruments becomes critical. Our Contamination Control Strategy and Implementation (CCSI) for the Sample Handling and Transfer System (SHTS) hardware (drill, scoop and funnels) included out-of-simulation protocol testing (out-of-sim) for hardware decontamination and verification during the 6-Sol simulation (in-sim). The most effective five-step decontamination combined safer-to-use sterilants (3%_hydrogen-peroxide-activated 5%_sodium-hypochlorite), and in situ real-time verification by adenosine triphosphate (ATP) and Signs of Life Detector (SOLID) Fluorescence Immunoassay for characterization hardware bioburden and airborne contaminants. The 20- to 40-min protocol enabled a 4-log bioburden reduction down to <0.1 fmoles ATP detection limit (funnels and drill) to 0.2-0.7 fmoles (scoop) of total ATP. The (post-cleaning) hardware background was 0.3 to 1-2 attomoles ATP/cm2 (cleanliness benchmark background values) equivalent to ca. 1-10 colony forming unit (CFU)/cm2. Further, 60-100% of the in-sim hardware background was ≤3-4 bacterial cells/cm2, the threshold limit for Class <7 aseptic operations. Across the six Sols, the flux of airborne contaminants to the drill sites was ∼5 and ∼22 amoles ATP/(cm2·day), accounting for an unexpectedly high Fluorescence Intensity (FI) signal (FI: ∼6000) against aquatic cyanobacteria, but negligible anthropogenic contribution. The SOLID immunoassay also detected microorganisms from multiple habitats across the Atacama Desert (anoxic, alkaline/acidic microenvironments in halite fields, playas, and alluvial fans) in both airborne and post-cleaning hardware background. Finally, the hardware ATP background was 40-250 times lower than the ATP in cores. Similarly, the FI peaks (FImax) against the microbial taxa and molecular biomarkers detected in the post-cleaned hardware (FI: ∼1500-1600) were 5-10 times lower than biomarkers in drilled sediments, excluding significant interference with putative biomarker found in cores. Similar protocols enable the acquisition of contamination-free materials for ultra-sensitive instruments analysis and the integrity of scientific results. Their application can augment our scientific knowledge of the distribution of cryptic life on Mars-like grounds and support life-detection robotic and human-operated missions to Mars.
Collapse
Affiliation(s)
- Rosalba Bonaccorsi
- SETI Institute, Mountain View, California, USA
- NASA Ames Research Center, Moffett Field, California, USA
| | - Brian Glass
- NASA Ames Research Center, Moffett Field, California, USA
| | - Mercedes Moreno-Paz
- Department of Molecular Evolution, Centro de Astrobiología (INTA-CSIC), Madrid, Spain
| | | | - Kimberley Warren-Rhodes
- SETI Institute, Mountain View, California, USA
- NASA Ames Research Center, Moffett Field, California, USA
| | - Victor Parro
- Department of Molecular Evolution, Centro de Astrobiología (INTA-CSIC), Madrid, Spain
| | - Juan Manuel Manchado
- Department of Molecular Evolution, Centro de Astrobiología (INTA-CSIC), Madrid, Spain
| | | | | |
Collapse
|
5
|
Glass B, Bergman D, Parro V, Kobayashi L, Stoker C, Quinn R, Davila A, Willis P, Brinckerhoff W, Warren-Rhodes K, Wilhelm M, Caceres L, DiRuggiero J, Zacny K, Moreno-Paz M, Dave A, Seitz S, Grubisic A, Castillo M, Bonaccorsi R. The Atacama Rover Astrobiology Drilling Studies (ARADS) Project. Astrobiology 2023; 23:1245-1258. [PMID: 38054949 PMCID: PMC10750311 DOI: 10.1089/ast.2022.0126] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 09/01/2023] [Indexed: 12/07/2023]
Abstract
With advances in commercial space launch capabilities and reduced costs to orbit, humans may arrive on Mars within a decade. Both to preserve any signs of past (and extant) martian life and to protect the health of human crews (and Earth's biosphere), it will be necessary to assess the risk of cross-contamination on the surface, in blown dust, and into the near-subsurface (where exploration and resource-harvesting can be reasonably anticipated). Thus, evaluating for the presence of life and biosignatures may become a critical-path Mars exploration precursor in the not-so-far future, circa 2030. This Special Collection of papers from the Atacama Rover Astrobiology Drilling Studies (ARADS) project describes many of the scientific, technological, and operational issues associated with searching for and identifying biosignatures in an extreme hyperarid region in Chile's Atacama Desert, a well-studied terrestrial Mars analog environment. This paper provides an overview of the ARADS project and discusses in context the five other papers in the ARADS Special Collection, as well as prior ARADS project results.
Collapse
Affiliation(s)
- B. Glass
- NASA Ames Research Center, Moffett Field, California, USA
| | - D. Bergman
- Honeybee Robotics, Pasadena, California, USA
| | - V. Parro
- Centro de Astrobiología (CAB), CSIC-INTA, Torrejon de Ardoz, Spain
| | - L. Kobayashi
- NASA Ames Research Center, Moffett Field, California, USA
| | - C. Stoker
- NASA Ames Research Center, Moffett Field, California, USA
| | - R. Quinn
- NASA Ames Research Center, Moffett Field, California, USA
| | - A. Davila
- NASA Ames Research Center, Moffett Field, California, USA
| | - P. Willis
- NASA Jet Propulsion Laboratory, Pasadena, California, USA
| | | | - K. Warren-Rhodes
- NASA Ames Research Center, Moffett Field, California, USA
- SETI Institute, Carl Sagan Center, Mountain View, California, USA
| | - M.B. Wilhelm
- NASA Ames Research Center, Moffett Field, California, USA
| | - L. Caceres
- University of Antofagasta, Antofagasta, Chile
| | | | - K. Zacny
- Honeybee Robotics, Pasadena, California, USA
| | - M. Moreno-Paz
- Centro de Astrobiología (CAB), CSIC-INTA, Torrejon de Ardoz, Spain
| | - A. Dave
- NASA Ames Research Center, Moffett Field, California, USA
| | - S. Seitz
- NASA Ames Research Center, Moffett Field, California, USA
| | - A. Grubisic
- NASA Goddard Space Flight Center, Greenbelt, Maryland, USA
| | - M. Castillo
- NASA Goddard Space Flight Center, Greenbelt, Maryland, USA
| | - R. Bonaccorsi
- NASA Ames Research Center, Moffett Field, California, USA
- SETI Institute, Carl Sagan Center, Mountain View, California, USA
| |
Collapse
|
6
|
Oertel M, Ziepert M, Nacke N, Frontzek F, Nickelsen M, Glass B, Poeschel V, Rube C, Lenz G, Schmitz N, Eich HTT. Radiotherapy in Young, High-Risk Patients with Aggressive B-cell Lymphoma: Long-Term Results from the Open-Label, Randomized, Phase 3 R-MegaCHOEP Trial. Int J Radiat Oncol Biol Phys 2023; 117:S63. [PMID: 37784542 DOI: 10.1016/j.ijrobp.2023.06.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The role of consolidative radiotherapy (RT) for young (< 60 years), high-risk patients with aggressive B-cell lymphoma is discussed. The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantation compared to conventional R-CHOEP immunochemotherapy for patients up to 60 years1,2. Despite no prognostic difference between treatment arms even after 10-year follow-up, excellent long-term results were achieved. The presented work represents a detailed RT-analysis providing long-term data on efficacy and side-effects. MATERIALS/METHODS The 10-year follow-up dataset of the R-MegaCHOEP trial with a median follow-up of 81.1 months (range 0.6-175.9 months) was used for this analysis. Indications for consolidative RT were extralymphatic involvement or bulky disease (maximum diameter ≥ 7.5 cm). Additionally, RT could be administered because of insufficient response at end of therapy as evaluated by CT scan. RESULTS Overall, 261 patients were analyzed, 120 of whom underwent RT. Patients with RT were predominantly male (65.8 %), had an age-adjusted IPI of 2 (75 %), an elevated LDH (96.7 %) and showed an ECOG-Score of 0-1 (65 %). Bulky disease was present in 103/120 patients in the RT-arm with a bulk size of 7.5-20.0 cm (median: 11 cm) and was located predominantly in the mediastinal (44), paraaortal (17) and mesenteric (13) regions. The most frequently irradiated regions were the mediastinal (50), paraaortic (27) and mesenteric (15) regions. Median RT dose was 36 Gray in median fractions of 1.8 Gray. Toxicities were generally mild to moderate with 24 and 8 grade 3 and 4 toxicities reported during RT. During long-term follow-up, 23 secondary malignancies occurred, with RT being no significant contributing risk factor (p = 0.188). Analysis of the overall study population showed that patients with RT had an improved event-free survival (EFS; 63.9 % vs. 46.0 %; p<0.001) and progression-free survival (PFS; 67.2 % vs. 54.1 %; p = 0.025) but not overall survival (OS; 72.8 % vs. 65.9 %; p = 0.132) in comparison to non-irradiated patients after 10 years. Considering only those patients with RT after a complete remission/unconfirmed complete remission after systemic therapy, a significantly improved EFS (66.4 % vs. 46.0 %; p = 0.006), but not PFS and OS, was shown (PFS: p = 0.054; OS: p = 0.222). For patients with bulky disease, RT resulted in a significantly better outcome (10-year EFS: 64.4 % vs. 34.5 %; p<0.001; 10-year PFS: 68.3 % vs. 47.4 %; p = 0.003; 10-year OS: 71.5 % vs. 59.4 %; p = 0.011), when compared to patients without RT. For patients with extralymphatic involvement, RT improved EFS (10-year EFS: 61.7 % vs. 51.1 %; p = 0.017), but not PFS or OS (PFS: p = 0.068; OS: p = 0.305). CONCLUSION RT improved outcome in young, high-risk patients with aggressive B-cell lymphoma and bulky disease. TRIAL REGISTRATION NUMBER NCT00129090. LITERATURE 1 Lancet Oncol 2012;13(12):1250-1259. 2 Lancet Haematol 2021;8(4):e267-e277.
Collapse
Affiliation(s)
- M Oertel
- Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany
| | - M Ziepert
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - N Nacke
- Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany
| | - F Frontzek
- Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, Muenster, Germany
| | | | - B Glass
- Clinic for Haematology, Oncology, Tumour Immunology, and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany
| | - V Poeschel
- Saarland University Medical School, Homburg, Germany
| | - C Rube
- Department of Radiation Oncology, Saarland University Hospital, Homburg, Germany
| | - G Lenz
- Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, Muenster, Germany
| | - N Schmitz
- Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, Muenster, Germany
| | - H T T Eich
- Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany
| |
Collapse
|
7
|
Michener C, Kirkup C, Rahsepar B, Iyer J, Abel J, Leidal K, Khosla A, Trotter B, Lin M, Resnick M, Glass B, Wapinski I, Najdawi F. 593P AI-powered analysis of nuclear morphology associated with prognosis in high-grade serous carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Dreger P, Ngoya M, Litovich C, Finel H, Herrera AF, Sauter C, Kharfan‐Dabaja M, Sureda A, Blaise D, Castagna L, Corradini P, Pastano R, Arat M, Boumendil A, Dietrich S, Schmitz N, Glass B, Montoto S, Hamadani M. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS. Hematol Oncol 2021. [DOI: 10.1002/hon.53_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Dreger
- EBMT Lymphoma Working Party Paris France
| | - M. Ngoya
- EBMT Lymphoma Working Party Paris France
| | - C. Litovich
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - H. Finel
- EBMT Lymphoma Working Party Paris France
| | - A. F Herrera
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - C. Sauter
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | | | - A. Sureda
- EBMT Lymphoma Working Party Paris France
| | - D. Blaise
- EBMT Lymphoma Working Party Paris France
| | | | | | - R. Pastano
- EBMT Lymphoma Working Party Paris France
| | - M. Arat
- EBMT Lymphoma Working Party Paris France
| | | | | | - N. Schmitz
- EBMT Lymphoma Working Party Paris France
| | - B. Glass
- EBMT Lymphoma Working Party Paris France
| | - S. Montoto
- EBMT Lymphoma Working Party Paris France
| | - M. Hamadani
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| |
Collapse
|
9
|
Taylor S, Cairns A, Glass B. Application of the PRECEDE-PROCEED model for the development of a community pharmacy ear health intervention for rural populations. International Journal of Pharmacy Practice 2021. [DOI: 10.1093/ijpp/riab016.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
The World Health Organisation has identified ear disease to be a major public health problem in rural and remote communities, with access to services an identified barrier. (1) Rural community pharmacists are recognised as highly skilled, accessible and trusted health professionals. An innovative service “LISTEN UP” (Locally Integrated Screening and Testing Ear aNd aUral Program) has been implemented in two remote community pharmacies in Australia. The service involves patients with an ear complaint self-presenting to a participating pharmacy and receiving a clinical examination by a pharmacist, who has completed accredited training in ear health, otoscopy and tympanometry. “LISTEN UP” has been developed using the PRECEDE-PROCEED planning model.(2) The PRECEDE component of the model assesses social, epidemiological, behavioural, environmental, educational and ecological factors to inform the development of an intervention.(2) The PROCEED-component consists of pilot testing and evaluation.
Aim
To describe an ecological approach to health promotion via the application of the PRECEDE-PROCEED planning model to develop a rural community pharmacy-based ear health intervention.
Methods
PRECEDE (Predisposing, Reinforcing, and Enabling Constructs in Educational Diagnosis) provided a framework to plan and develop a locally relevant and community focused program. This included research and engagement via meetings, surveys and interviews of consumers, pharmacists, health professionals and stakeholders. PROCEED (Policy, Regulatory, and Organisational Constructs in Educational and Environmental Development) outlined the structure for implementing and evaluating the intervention that was developed in the PRECEDE process. A pilot study has been included in PROCEED segment to allow improvement before implementing and evaluating the final model. Data will be collected in the pilot study via semi-structured interviews and surveys. This will be analysed using descriptive statistics and thematic analysis of qualitative data.
Results
As part of the PRECEDE segment a social assessment was undertaken via mixed method studies of rural consumers, pharmacists and health professionals. Hearing testing was ranked as the seventh (from twenty-six) most important expanded pharmacy service by both consumer and health professional groups. An epidemiological assessment found extensive ear disease in rural and remote locations resulting in complications and hearing loss. Behavioural and environment assessments identified eleven ear health interventions which include hearing screening [3], otoscopy pilot studies [2], audiometry services [1], specific education for undergraduate pharmacy students [2] and a pharmacy-based clinic [3]. However none of the interventions described a framework for continued service provision. Policy and regulation assessment was undertaken to align the intervention within the regulatory framework. The application of this model is partially complete with the study protocol for the intervention developed and the initial pilot study in progress. This study’s strengths include its applicability to rural populations and the limited evidence base that currently exists. It is however limited by the small size of the pilot study and application of this model to a national intervention would be useful for future.
Conclusions
The application of the PRECEDE-PROCEED model demonstrates the applicability of this planning model for developing and evaluating an ear health intervention with a particular focus on community pharmacies in rural and remote locations.
References
1. World Health Organisation. Deafness and hearing loss; 2020. Available from: https://www.who.int/health-topics/hearing-loss#tab=tab_1 [Accessed: 15/9/2020]
2. Binkley CJ, Johnson KW. Application of the PRECEDE-PROCEED Planning Model in Designing an Oral Health Strategy. J Theory Pract Dent Public Health. 2013;1(3):http://www.sharmilachatterjee.com/ojs-2.3.8/index.php/JTPDPH/article/view/89
Collapse
Affiliation(s)
- S Taylor
- Centre for Rural and Remote Health – Mount Isa, Australia
| | - A Cairns
- Centre for Rural and Remote Health – Mount Isa, Australia
| | - B Glass
- James Cook University, Townsville, Australia
| |
Collapse
|
10
|
Sánchez-García L, Fernández-Martínez MA, Moreno-Paz M, Carrizo D, García-Villadangos M, Manchado JM, Stoker CR, Glass B, Parro V. Simulating Mars Drilling Mission for Searching for Life: Ground-Truthing Lipids and Other Complex Microbial Biomarkers in the Iron-Sulfur Rich Río Tinto Analog. Astrobiology 2020; 20:1029-1047. [PMID: 31916858 PMCID: PMC7499885 DOI: 10.1089/ast.2019.2101] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2019] [Accepted: 11/18/2019] [Indexed: 05/19/2023]
Abstract
Sulfate and iron oxide deposits in Río Tinto (Southwestern Spain) are a terrestrial analog of early martian hematite-rich regions. Understanding the distribution and drivers of microbial life in iron-rich environments can give critical clues on how to search for biosignatures on Mars. We simulated a robotic drilling mission searching for signs of life in the martian subsurface, by using a 1m-class planetary prototype drill mounted on a full-scale mockup of NASA's Phoenix and InSight lander platforms. We demonstrated fully automated and aseptic drilling on iron and sulfur rich sediments at the Río Tinto riverbanks, and sample transfer and delivery to sterile containers and analytical instruments. As a ground-truth study, samples were analyzed in the field with the life detector chip immunoassay for searching microbial markers, and then in the laboratory with X-ray diffraction to determine mineralogy, gas chromatography/mass spectrometry for lipid composition, isotope-ratio mass spectrometry for isotopic ratios, and 16S/18S rRNA genes sequencing for biodiversity. A ubiquitous presence of microbial biomarkers distributed along the 1m-depth subsurface was influenced by the local mineralogy and geochemistry. The spatial heterogeneity of abiotic variables at local scale highlights the importance of considering drill replicates in future martian drilling missions. The multi-analytical approach provided proof of concept that molecular biomarkers varying in compositional nature, preservation potential, and taxonomic specificity can be recovered from shallow drilling on iron-rich Mars analogues by using an automated life-detection lander prototype, such as the one proposed for NASA's IceBreaker mission proposal.
Collapse
Affiliation(s)
- Laura Sánchez-García
- Centro de Astrobiología (CSIC-INTA), Madrid, Spain
- Address correspondence to: Laura Sánchez-García, Centro de Astrobiología (CSIC-INTA), Carretera de Ajalvir km 4, Torrejón de Ardoz, Madrid 28850, Spain
| | | | | | | | | | | | | | - Brian Glass
- NASA Ames Research Center, Moffett Field, California
| | - Victor Parro
- Centro de Astrobiología (CSIC-INTA), Madrid, Spain
| |
Collapse
|
11
|
Abdullayev E, Abdullayev E, Baurmann H, Fuhrmann S, Glass B. CD34+ selected stem cell boost for CMV induced poor graft function after allogeneic stem cell transplantation. Leuk Res 2019. [DOI: 10.1016/s0145-2126(19)30310-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Abdullayev E, Abdullayev E, Baurmann H, Eimermacher C, Glass B. POEMS syndrome treated with autologous hematopoietic stem cell transplantation. Leuk Res 2019. [DOI: 10.1016/s0145-2126(19)30309-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Wilhelm MB, Davila AF, Parenteau MN, Jahnke LL, Abate M, Cooper G, Kelly ET, Parro García V, Villadangos MG, Blanco Y, Glass B, Wray JJ, Eigenbrode JL, Summons RE, Warren-Rhodes K. Constraints on the Metabolic Activity of Microorganisms in Atacama Surface Soils Inferred from Refractory Biomarkers: Implications for Martian Habitability and Biomarker Detection. Astrobiology 2018; 18:955-966. [PMID: 30035640 DOI: 10.1089/ast.2017.1705] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Dryness is one of the main environmental challenges to microbial survival. Understanding the threshold of microbial tolerance to extreme dryness is relevant to better constrain the environmental limits of life on Earth and critically evaluate long-term habitability models of Mars. Biomolecular proxies for microbial adaptation and growth were measured in Mars-like hyperarid surface soils in the Atacama Desert that experience only a few millimeters of precipitation per decade, and in biologically active soils a few hundred kilometers away that experience two- to fivefold more precipitation. Diversity and abundance of lipids and other biomolecules decreased with increasing dryness. Cyclopropane fatty acids (CFAs), which are indicative of adaptive response to environmental stress and growth in bacteria, were only detected in the wetter surface soils. The ratio of trans to cis isomers of an unsaturated fatty acid, another bacterial stress indicator, decreased with increasingly dry conditions. Aspartic acid racemization ratios increased from 0.01 in the wetter soils to 0.1 in the driest soils, which is indicative of racemization rates comparable to de novo biosynthesis over long timescales (∼10,000 years). The content and integrity of stress proteins profiled by immunoassays were additional indicators that biomass in the driest soils is not recycled at significant levels. Together, our results point to minimal or no in situ microbial growth in the driest surface soils of the Atacama, and any metabolic activity is likely to be basal for cellular repair and maintenance only. Our data add to a growing body of evidence that the driest Atacama surface soils represent a threshold for long-term habitability (i.e., growth and reproduction). These results place constraints on the potential for extant life on the surface of Mars, which is 100-1000 times drier than the driest regions in the Atacama. Key Words: Atacama Desert-Dryness-Growth-Habitability-Biomarker-Mars. Astrobiology 18, 955-966.
Collapse
Affiliation(s)
- Mary Beth Wilhelm
- 1 School of Earth and Atmospheric Sciences, Georgia Institute of Technology , Atlanta, Georgia
- 2 Space Science and Astrobiology Division, NASA Ames Research Center , Moffett Field, California
| | - Alfonso F Davila
- 2 Space Science and Astrobiology Division, NASA Ames Research Center , Moffett Field, California
| | - Mary N Parenteau
- 2 Space Science and Astrobiology Division, NASA Ames Research Center , Moffett Field, California
| | - Linda L Jahnke
- 2 Space Science and Astrobiology Division, NASA Ames Research Center , Moffett Field, California
| | - Mastewal Abate
- 2 Space Science and Astrobiology Division, NASA Ames Research Center , Moffett Field, California
| | - George Cooper
- 2 Space Science and Astrobiology Division, NASA Ames Research Center , Moffett Field, California
| | | | - Victor Parro García
- 4 Departamento Evolución Molecular, Centro de Astrobiologia (INTA-CSIC) , Madrid, Spain
| | - Miriam G Villadangos
- 4 Departamento Evolución Molecular, Centro de Astrobiologia (INTA-CSIC) , Madrid, Spain
| | - Yolanda Blanco
- 4 Departamento Evolución Molecular, Centro de Astrobiologia (INTA-CSIC) , Madrid, Spain
| | - Brian Glass
- 5 Intelligent Systems Division, NASA Ames Research Center , Moffett Field, California
| | - James J Wray
- 1 School of Earth and Atmospheric Sciences, Georgia Institute of Technology , Atlanta, Georgia
| | - Jennifer L Eigenbrode
- 6 Planetary Environments Laboratory, NASA Goddard Space Flight Center , Greenbelt, Maryland
| | - Roger E Summons
- 7 Department of Earth, Atmospheric, and Planetary Sciences, Massachusetts Institute of Technology , Cambridge, Massachusetts
| | | |
Collapse
|
14
|
Glass B, Dohm A, Truemper L, Pfreundschuh M, Bleckmann A, Wulf G, Rosenwald A, Ziepert M, Schmitz N. Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial. Ann Oncol 2017; 28:3058-3064. [DOI: 10.1093/annonc/mdx556] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Yue EW, Sparks R, Polam P, Modi D, Douty B, Wayland B, Glass B, Takvorian A, Glenn J, Zhu W, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Emm T, Scherle PA, Metcalf B, Combs AP. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. ACS Med Chem Lett 2017; 8:486-491. [PMID: 28523098 PMCID: PMC5430407 DOI: 10.1021/acsmedchemlett.6b00391] [Citation(s) in RCA: 188] [Impact Index Per Article: 26.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Accepted: 02/24/2017] [Indexed: 01/25/2023] Open
Abstract
![]()
A data-centric medicinal
chemistry approach led to the invention
of a potent and selective IDO1 inhibitor 4f, INCB24360
(epacadostat). The molecular structure of INCB24360 contains several
previously unknown or underutilized functional groups in drug substances,
including a hydroxyamidine, furazan, bromide, and sulfamide. These
moieties taken together in a single structure afford a compound that
falls outside of “drug-like” space. Nevertheless, the in vitro ADME data is consistent with the good cell permeability
and oral bioavailability observed in all species (rat, dog, monkey)
tested. The extensive intramolecular hydrogen bonding observed in
the small molecule crystal structure of 4f is believed
to significantly contribute to the observed permeability and PK. Epacadostat
in combination with anti-PD1 mAb pembrolizumab is currently being
studied in a phase 3 clinical trial in patients with unresectable
or metastatic melanoma.
Collapse
Affiliation(s)
- Eddy W. Yue
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Richard Sparks
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Padmaja Polam
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Dilip Modi
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Brent Douty
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Brian Wayland
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Brian Glass
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Amy Takvorian
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Joseph Glenn
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Wenyu Zhu
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Michael Bower
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Xiangdong Liu
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Lynn Leffet
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Qian Wang
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Kevin J. Bowman
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Michael J. Hansbury
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Min Wei
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Yanlong Li
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Richard Wynn
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Timothy C. Burn
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Holly K. Koblish
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Jordan S. Fridman
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Tom Emm
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Peggy A. Scherle
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Brian Metcalf
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| | - Andrew P. Combs
- Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States
| |
Collapse
|
16
|
Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 2016; 51:51-7. [PMID: 26367239 DOI: 10.1038/bmt.2015.213] [Citation(s) in RCA: 187] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 07/31/2015] [Indexed: 01/21/2023]
Abstract
Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.
Collapse
Affiliation(s)
| | - N Schmitz
- AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany
| | | | - D Gill
- Princess Alexandra Hospital, Woodville, SA, Australia
| | - D Linch
- University College London, Cancer Institute, London, UK
| | - M Trneny
- Charles Univ. General Hosp., Praha, Czech Republic
| | - N Milpied
- Hématologie Clinique et thérapie cellulaire, Hôpital Haut-Lévêque, Pessac, France
| | - J Radford
- University of Manchester, c/o Department of Medical Oncology, Christie Hospital NHS, Manchester, UK
| | - N Ketterer
- Clinique Bois-Cerf, Lausanne, Switzerland
| | | | - U Dührsen
- Universitätsklinikum Essen, KlinikfürHämatologie, Essen, Germany
| | - D Ma
- St Vincent's Hospital Sydney, Darlinghurst, NW, Australia
| | - J Brière
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| | - C Thieblemont
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| | - G Salles
- Hospices Civils de Lyon, Service d'Hématologie, Université de Lyon, Lyon, France
| | - C H Moskowitz
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - B Glass
- AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany
| | - C Gisselbrecht
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| |
Collapse
|
17
|
Höhn K, Fuchs J, Fröber A, Kirmse R, Glass B, Anders-Össwein M, Walther P, Kräusslich HG, Dietrich C. Preservation of protein fluorescence in embedded human dendritic cells for targeted 3D light and electron microscopy. J Microsc 2015; 259:121-128. [PMID: 25786567 PMCID: PMC4757415 DOI: 10.1111/jmi.12230] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Accepted: 01/28/2015] [Indexed: 11/28/2022]
Abstract
In this study, we present a correlative microscopy workflow to combine detailed 3D fluorescence light microscopy data with ultrastructural information gained by 3D focused ion beam assisted scanning electron microscopy. The workflow is based on an optimized high pressure freezing/freeze substitution protocol that preserves good ultrastructural detail along with retaining the fluorescence signal in the resin embedded specimens. Consequently, cellular structures of interest can readily be identified and imaged by state of the art 3D confocal fluorescence microscopy and are precisely referenced with respect to an imprinted coordinate system on the surface of the resin block. This allows precise guidance of the focused ion beam assisted scanning electron microscopy and limits the volume to be imaged to the structure of interest. This, in turn, minimizes the total acquisition time necessary to conduct the time consuming ultrastructural scanning electron microscope imaging while eliminating the risk to miss parts of the target structure. We illustrate the value of this workflow for targeting virus compartments, which are formed in HIV-pulsed mature human dendritic cells.
Collapse
Affiliation(s)
- K Höhn
- Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany
| | - J Fuchs
- Carl Zeiss AG, Oberkochen, Germany
| | - A Fröber
- Carl Zeiss AG, Oberkochen, Germany
| | - R Kirmse
- Carl Zeiss Microscopy GmbH, Jena, Germany
| | - B Glass
- Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany
| | - M Anders-Össwein
- Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany
| | - P Walther
- Electron Microscopy Facility, Ulm University, Ulm, Germany
| | - H-G Kräusslich
- Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany
| | | |
Collapse
|
18
|
Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TFE, Bernd HW, Feller AC, Klapper W, Stuhlmann-Laeisz C, Hummel M, Stein H, Lenze D, Hartmann S, Hansmann ML, Möller P, Cogliatti S, Pfreundschuh M, Trümper L, Loeffler M, Glass B, Schmitz N, Ott G, Rosenwald A. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia 2015; 29:1564-70. [DOI: 10.1038/leu.2015.43] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 02/05/2015] [Accepted: 02/06/2015] [Indexed: 02/02/2023]
|
19
|
Palanivel S, Nelaturu P, Glass B, Mishra R. Friction stir additive manufacturing for high structural performance through microstructural control in an Mg based WE43 alloy. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.matdes.2014.09.082] [Citation(s) in RCA: 146] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Glass B. Occupational health in New Zealand: where from? where to? Intern Med J 2014; 44:831-3. [DOI: 10.1111/imj.12531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Accepted: 07/07/2014] [Indexed: 11/27/2022]
Affiliation(s)
- B. Glass
- WorkSafe; Wellington New Zealand
| |
Collapse
|
21
|
Zacny K, Paulsen G, McKay CP, Glass B, Davé A, Davila AF, Marinova M, Mellerowicz B, Heldmann J, Stoker C, Cabrol N, Hedlund M, Craft J. Reaching 1 m deep on Mars: the Icebreaker drill. Astrobiology 2013; 13:1166-1198. [PMID: 24303959 DOI: 10.1089/ast.2013.1038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The future exploration of Mars will require access to the subsurface, along with acquisition of samples for scientific analysis and ground-truthing of water ice and mineral reserves for in situ resource utilization. The Icebreaker drill is an integral part of the Icebreaker mission concept to search for life in ice-rich regions on Mars. Since the mission targets Mars Special Regions as defined by the Committee on Space Research (COSPAR), the drill has to meet the appropriate cleanliness standards as requested by NASA's Planetary Protection Office. In addition, the Icebreaker mission carries life-detection instruments; and in turn, the drill and sample delivery system have to meet stringent contamination requirements to prevent false positives. This paper reports on the development and testing of the Icebreaker drill, a 1 m class rotary-percussive drill and triple redundant sample delivery system. The drill acquires subsurface samples in short, approximately 10 cm bites, which makes the sampling system robust and prevents thawing and phase changes in the target materials. Autonomous drilling, sample acquisition, and sample transfer have been successfully demonstrated in Mars analog environments in the Arctic and the Antarctic Dry Valleys, as well as in a Mars environmental chamber. In all environments, the drill has been shown to perform at the "1-1-100-100" level; that is, it drilled to 1 m depth in approximately 1 hour with less than 100 N weight on bit and approximately 100 W of power. The drilled substrate varied and included pure ice, ice-rich regolith with and without rocks and with and without 2% perchlorate, and whole rocks. The drill is currently at a Technology Readiness Level (TRL) of 5. The next-generation Icebreaker drill weighs 10 kg, which is representative of the flightlike model at TRL 5/6.
Collapse
Affiliation(s)
- K Zacny
- 1 Honeybee Robotics , Pasadena, California
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
|
23
|
Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, Haenel M, Loeffler M, Truemper L, Pfreundschuh M. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012; 23:1267-1273. [PMID: 21989328 DOI: 10.1093/annonc/mdr440] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND To describe incidence, risk factors, and influence of treatment on occurrence of central nervous system (CNS) relapse or progression in younger patients with aggressive B-cell lymphoma. PATIENTS AND METHODS We analyzed 2210 patients with aggressive B-cell lymphoma treated on various studies for CNS relapse/progression. Treatment consisted of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) ± etoposide. Six hundred and twenty patients also received rituximab. CNS prophylaxis was intrathecal methotrexate on High-CHOEP and MegaCHOEP phase III studies if upper neck, head, bone marrow, or testes were involved. RESULTS Fifty-six of 2196 patients (2.6%) developed CNS disease. It occurred early (median 7.0 months), median survival was 5.0 months. Patients with age-adjusted International Prognostic Index (aaIPI) 0 or 1 treated with rituximab showed a low risk for CNS disease (2-year rates: 0% or 0.5%), and rituximab decreased the risk (relative risk 0.3, 95% confidence interval 0.1-0.9, P = 0.029). Patients with aaIPI 2 or 3 showed a moderate risk (4.2%-9.7%) and no significant reduction of CNS disease with rituximab. CNS prophylaxis was of no significant benefit. CONCLUSIONS In younger patients with aaIPI 0 or 1, CNS relapse/progression is very rare; in patients with aaIPI 2 or 3, the risk is higher (up to 10%) and requires new diagnostic strategies and treatment.
Collapse
MESH Headings
- Adolescent
- Adult
- Age of Onset
- Antibodies, Monoclonal, Murine-Derived/administration & dosage
- Antibodies, Monoclonal, Murine-Derived/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Central Nervous System Neoplasms/drug therapy
- Central Nervous System Neoplasms/epidemiology
- Central Nervous System Neoplasms/secondary
- Clinical Trials, Phase II as Topic/statistics & numerical data
- Clinical Trials, Phase III as Topic/statistics & numerical data
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/adverse effects
- Cyclophosphamide/therapeutic use
- Doxorubicin/administration & dosage
- Doxorubicin/adverse effects
- Doxorubicin/therapeutic use
- Etoposide/administration & dosage
- Etoposide/adverse effects
- Etoposide/therapeutic use
- Female
- Germany/epidemiology
- Humans
- International Cooperation
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/epidemiology
- Lymphoma, B-Cell/pathology
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/epidemiology
- Lymphoma, Non-Hodgkin/pathology
- Male
- Medical Oncology/organization & administration
- Methotrexate/administration & dosage
- Methotrexate/adverse effects
- Middle Aged
- Multicenter Studies as Topic
- Neoplasm Grading
- Neoplasm Invasiveness
- Prednisolone/administration & dosage
- Prednisolone/adverse effects
- Prednisolone/therapeutic use
- Prednisone/administration & dosage
- Prednisone/adverse effects
- Prednisone/therapeutic use
- Rituximab
- Societies, Medical/organization & administration
- Vincristine/administration & dosage
- Vincristine/adverse effects
- Vincristine/therapeutic use
- Young Adult
Collapse
Affiliation(s)
- N Schmitz
- Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St. Georg, Hamburg.
| | - S Zeynalova
- Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig
| | - B Glass
- Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St. Georg, Hamburg
| | - U Kaiser
- Internal Medicine II-Oncology Center, Hematology, Immunology, Internal Oncology, Palliative Medicine, St. Bernward Hospital, Hildesheim, Germany
| | | | - M Wolf
- Peter MacCallum Cancer Institute, Division of Haematology, East Melbourne, Australia
| | - M Haenel
- Internal Medicine III, Department of Hematology, Oncology, Stem Cell Transplantation, Klinikum Chemnitz, Chemnitz
| | - M Loeffler
- Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig
| | - L Truemper
- Department of Hematology and Oncology, University of Göttingen, Göttingen
| | - M Pfreundschuh
- Department of Internal Medicine I, Saarland University, Homburg/Saar, Germany
| |
Collapse
|
24
|
Gisselbrecht C, Glass B, Laurent G, Gill DS, Linch MD, Trneny M, Bron D, Shpilberg O, Hagberg H, Bargetzi M, Ma D, Briere J, Moskowitz C, Schmitz N. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Truemper LH, Loeffler M, Pfreundschuh M, Glass B. Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Glass B, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, Pfreundschuh M, Schmitz N, Truemper LH, Wulf G. The impact of high-intensity conditioning prior to allogeneic stem cell transplantation in patients with chemorefractory or relapsed T-cell lymphoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Poeschel V, Murawski N, Glass B, Zeynalova S, Fleckenstein J, Ziepert M, Kempf B, Loeffler M, Schmitz N, Pfreundschuh M. Aggressive craniofacial lymphoma in the pre-rituximab and rituximab era. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Abstract
Dose administration aid (DAA) usage has become increasingly prevalent among populations worldwide and as such has become an important part of pharmacy practice. The evidence for the use of these aids has been favourable in Australia resulting in 2006 in a community based DAA program being considered by the Australian Government Department of Health and Ageing PPSAC (Professional Programs and Services Advisory Committee) and the first phase of this program implemented in October 2007. The program was established under the Better Community Health Initiative of the 4(th) Community Pharmacy Agreement between the Pharmacy Guild of Australia and the Commonwealth Government. The aim of this program is to reduce medication-related hospitalisations and adverse events through improved medication management and adherence by people in the community. The most common patient groups that access this service include the elderly, who are often on several different medications, and patients with cognitive disabilities who may have trouble understanding or remembering their dosage regimes.Repackaging of a medication, involving removal from its primary packaging invalidates the stability guarantee of the manufacturer. It is in fact the role of the healthcare team to ensure optimal patient care by making an informed judgment as to the effect on the quality and safety of this repackaging process. Drug manufacturers, on the whole, tend to discourage repackaging of medications and there is little quality data available to support this process. Indeed, only a small number of medications have been investigated for their stability following repackaging into DAAs, namely atenolol, paracetamol, frusemide, prochlorperazine, sodium valproate, aspirin (dosette boxes) and clozapine. This paper will review the repackaging of medications into DAAs and the role that the pharmacist plays in this process to improve patient care, in addition to presenting the Australian research that has contributed substantially to the body of information available internationally on the quality implications, relating to the stability of medicines repackaged into DAAs.
Collapse
Affiliation(s)
- A Haaywood
- School of Pharmacy, Gold Coast Campus, Griffith University, QLD 4222
| | | | | | | | | |
Collapse
|
29
|
Haaywood A, Llewelyn V, Robertson S, Mylrea M, Glass B. Dose administration aids: Pharmacists' role in improving patient care. Australas Med J 2011; 4:183-9. [PMID: 23049624 DOI: 10.4066/amj.2011693] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Dose administration aid (DAA) usage has become increasingly prevalent among populations worldwide and as such has become an important part of pharmacy practice. The evidence for the use of these aids has been favourable in Australia resulting in 2006 in a community based DAA program being considered by the Australian Government Department of Health and Ageing PPSAC (Professional Programs and Services Advisory Committee) and the first phase of this program implemented in October 2007. The program was established under the Better Community Health Initiative of the 4(th) Community Pharmacy Agreement between the Pharmacy Guild of Australia and the Commonwealth Government. The aim of this program is to reduce medication-related hospitalisations and adverse events through improved medication management and adherence by people in the community. The most common patient groups that access this service include the elderly, who are often on several different medications, and patients with cognitive disabilities who may have trouble understanding or remembering their dosage regimes.Repackaging of a medication, involving removal from its primary packaging invalidates the stability guarantee of the manufacturer. It is in fact the role of the healthcare team to ensure optimal patient care by making an informed judgment as to the effect on the quality and safety of this repackaging process. Drug manufacturers, on the whole, tend to discourage repackaging of medications and there is little quality data available to support this process. Indeed, only a small number of medications have been investigated for their stability following repackaging into DAAs, namely atenolol, paracetamol, frusemide, prochlorperazine, sodium valproate, aspirin (dosette boxes) and clozapine. This paper will review the repackaging of medications into DAAs and the role that the pharmacist plays in this process to improve patient care, in addition to presenting the Australian research that has contributed substantially to the body of information available internationally on the quality implications, relating to the stability of medicines repackaged into DAAs.
Collapse
Affiliation(s)
- A Haaywood
- School of Pharmacy, Gold Coast Campus, Griffith University, QLD 4222
| | | | | | | | | |
Collapse
|
30
|
Glass B, Ziepert M, Reiser M, Freund M, Trümper L, Metzner B, Feller A, Loeffler M, Pfreundschuh M, Schmitz N. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol 2010; 21:2255-2261. [DOI: 10.1093/annonc/mdq235] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Glass B. [Prophylaxis of fungal infections in haematological patients: pro]. Dtsch Med Wochenschr 2010; 135:1870. [PMID: 20842607 DOI: 10.1055/s-0030-1263329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- B Glass
- Abteilung Hämatologie und Stammzelltransplantation, Asklepios-Klinik St. Georg, Hamburg.
| |
Collapse
|
32
|
Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, Mueller-Hermelink H, Pfreundschuh M, Schmitz N. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009; 20:1977-84. [DOI: 10.1093/annonc/mdp211] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
33
|
Parrish D, Glass B, Rehberg GM, Kastner ME. 4,5-Dichloro-2H-1,3-oxazine-2,6(3H)-dione. Acta Crystallogr Sect E Struct Rep Online 2009; 65:o2356. [PMID: 21577825 PMCID: PMC2970364 DOI: 10.1107/s1600536809034606] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2009] [Accepted: 08/28/2009] [Indexed: 11/11/2022]
Abstract
In the title compound, C(4)HCl(2)NO(3), the essentially planar (maximum deviation = 0.023 Å for the ring O atom) mol-ecules form N-H⋯O hydrogen bonds between mol-ecules lying about inversion centers, forming eight-membered rings with an R(2) (2)(8) motif in graph-set notation.
Collapse
Affiliation(s)
- Damon Parrish
- Department of Chemistry, Bucknell University, Lewisburg, PA 17837, USA
| | | | | | | |
Collapse
|
34
|
Abstract
BACKGROUND AND OBJECTIVE Patients are increasingly requiring their medications to be repackaged into dose administration aids because of the positive outcomes associated with reduction in medication related hospitalization and adverse effects due to improved medicines management. Since the stability of these repackaged medications is not the responsibility of manufacturer, it is important that drug substances with potential stability issues be identified. Thus the objective of this study was to evaluate the stability of prochlorperazine, a light sensitive drug repackaged into dose administration aids (DAAs), in order to provide guidelines to the pharmacist and advice to the patient on appropriate storage. METHODS Prochlorperazine tablets were stored repackaged in DAAs and in their original packaging for 8 weeks at ambient (25 +/- 1 degrees C; 60 +/- 1.5% RH), accelerated (40 +/- 1 degrees C; 75 +/- 1.5% RH) and in-use conditions encountered in situ both in a pharmacy and the patients' home. They were assessed for both chemical (using a validated HPLC method) and physical stability according to British Pharmacopoeial (BP) standards. In addition, photostability testing was undertaken under ICH conditions. RESULTS AND DISCUSSION Chemical and physical stability was confirmed to be within BP Limits. There were, however, noticeable organoleptic changes in the tablets stored under in-use conditions with a progressive grey discolouration over the 8 weeks, starting in week 2. CONCLUSION Despite the confirmation of physical and chemical stability within BP limits, the discoloration and the potential for photodegradants to cause adverse effects in patients must lead us to draw the conclusion that the quality of this medication has been compromised. Pharmacists thus need to take this into account in repackaging and storage of prochlorperazine in DAAs and advise patients to store their DAA protected from light, heat and humidity.
Collapse
Affiliation(s)
- B Glass
- School of Pharmacy and Molecular Sciences, James Cook University, Townsville, Qld, Australia.
| | | | | |
Collapse
|
35
|
Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8509] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8509 Background: Salvage chemotherapy followed by high dose therapy and autologous stem cell transplantation (ASCT) is the standard of treatment for chemosensitive relapses in diffuse large B cell lymphoma. This intergroup trial compared the association rituximab, ifosfamide, etoposide, carboplatinum, R-ICE and rituximab dexamethasone aracytine and cisplatinum R-DHAP. Methods: DLBCL CD 20+ in first relapse or pts refractory after first line therapy were randomized between R-DHAP and R-ICE. Responding patients received BEAM and ASCT and were randomized between observation or maintenance with rituximab for 1 yr. Results: Intent to treat analysis was made on the first 396 pts randomized in 11 countries (R ICE:202; R DHAP:194): median age 55 yrs.; 225 relapses >12months, 166 refractory/early relapses; 244 pts with prior exposure to rituximab; Stage 3–4: 240 pts; elevated LDH: 198 pts; secondary IPI 0–1: 226 pts/ 2–3:149 pts. Patients with prior exposure to rituximab had more refractory disease and adverse prognostic factors. The overall response rate was 63%, with 38% complete remission. There was no difference in response rate between R-ICE 63.5% (CI 56–70%) and R-DHAP 62.8% (CI 55–69%), and in mobilization adjusted response rate. ASCT was performed in 206 pts. 90 SAE were reported in the R-ICE arm and 120 in the R-DHAP with 14 deaths. Factors significantly affecting response rate (p<.0001) were: refractory/relapse < 12 months:46 % vs 88 %, secondary IPI >1:52% vs 71% and prior exposure to rituximab:51% vs 83%. There was not significant difference between R-ICE and R-DHAP for 3 yr EFS (26% vs 35% p=0.6) and OS (47% vs 51%, p=0.5). Three yrs EFS was affected by: prior treatment with rituximab, 21% vs none 47% (p<.0001); early relapse< 12 m 20% vs >12m 45% (p <.0001); secondary IPI 2–3: 18% vs 0–1: 40% (p=.0001). In Cox model, all these parameters were significant (p<.0001) for EFS, PFS and OS but not the treatment arm. Longer follow up is necessary to evaluate the second randomization. Conclusions: There was no difference between R-ICE and R-DHAP. In pts without adverse prognostic factors a response rate > 80% was observed. However, early relapses/ refractory pts to upfront rituximab-based chemotherapy have a poor response rate and prognosis. [Table: see text]
Collapse
Affiliation(s)
- C. Gisselbrecht
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B. Glass
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - N. Mounier
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - D. Gill
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - D. Linch
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Trneny
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A. Bosly
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - O. Shpilberg
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - N. Ketterer
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C. Moskowitz
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - N. Schmitz
- Hopital Saint Louis, Paris, France; Asklepios Klinik St. Georg, Hamburg, Germany; CHU L'Archet, Nice, France; Princess Alexandra Hospital, Brisbane, Australia; University College London Hospital, London, United Kingdom; Charles University General Hospital, Praha, Czech Republic; UCL Mont Godinne, Yvoir, Belgium; Rabin Medical Center, Petah Tikva, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
36
|
Gleissner B, Kppers R, Siebert R, Glass B, Trmper L, Hiddemann W, Dreyling M. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. Br J Haematol 2008; 142:166-78. [DOI: 10.1111/j.1365-2141.2008.07138.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
37
|
Zacny K, Bar-Cohen Y, Brennan M, Briggs G, Cooper G, Davis K, Dolgin B, Glaser D, Glass B, Gorevan S, Guerrero J, McKay C, Paulsen G, Stanley S, Stoker C. Drilling systems for extraterrestrial subsurface exploration. Astrobiology 2008; 8:665-706. [PMID: 18598141 DOI: 10.1089/ast.2007.0179] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Drilling consists of 2 processes: breaking the formation with a bit and removing the drilled cuttings. In rotary drilling, rotational speed and weight on bit are used to control drilling, and the optimization of these parameters can markedly improve drilling performance. Although fluids are used for cuttings removal in terrestrial drilling, most planetary drilling systems conduct dry drilling with an auger. Chip removal via water-ice sublimation (when excavating water-ice-bound formations at pressure below the triple point of water) and pneumatic systems are also possible. Pneumatic systems use the gas or vaporization products of a high-density liquid brought from Earth, gas provided by an in situ compressor, or combustion products of a monopropellant. Drill bits can be divided into coring bits, which excavate an annular shaped hole, and full-faced bits. While cylindrical cores are generally superior as scientific samples, and coring drills have better performance characteristics, full-faced bits are simpler systems because the handling of a core requires a very complex robotic mechanism. The greatest constraints to extraterrestrial drilling are (1) the extreme environmental conditions, such as temperature, dust, and pressure; (2) the light-time communications delay, which necessitates highly autonomous systems; and (3) the mission and science constraints, such as mass and power budgets and the types of drilled samples needed for scientific analysis. A classification scheme based on drilling depth is proposed. Each of the 4 depth categories (surface drills, 1-meter class drills, 10-meter class drills, and deep drills) has distinct technological profiles and scientific ramifications.
Collapse
Affiliation(s)
- K Zacny
- Honeybee Robotics Spacecraft Mechanisms Corporation, New York, NY 10001, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
We describe results from the Drilling Automation for Mars Exploration (DAME) project, including those of the summer 2006 tests from an Arctic analog site. The drill hardware is a hardened, evolved version of the Advanced Deep Drill by Honeybee Robotics. DAME has developed diagnostic and executive software for hands-off surface operations of the evolved version of this drill. The DAME drill automation tested from 2004 through 2006 included adaptively controlled drilling operations and the downhole diagnosis of drilling faults. It also included dynamic recovery capabilities when unexpected failures or drilling conditions were discovered. DAME has developed and tested drill automation software and hardware under stressful operating conditions during its Arctic field testing campaigns at a Mars analog site.
Collapse
Affiliation(s)
- B Glass
- NASA Ames Research Center, Moffett Field, California 94035, USA.
| | | | | | | | | |
Collapse
|
39
|
Hasenkamp J, Borgerding A, Uhrberg M, Falk C, Chapuy B, Wulf G, Jung W, Trümper L, Glass B. Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors. Scand J Immunol 2008; 67:218-29. [PMID: 18226015 DOI: 10.1111/j.1365-3083.2007.02058.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Natural killer (NK) cells identify cells with altered human leucocyte antigen (HLA) expression as targets through lacking engagement of self-HLA-specific inhibitory receptors (e.g. killer cell immunoglobulin-like receptor, KIR). Thus, they eliminate cells with 'missing self' because of viral or malignant transformation. We performed analysis of HLA, KIR genotypes and KIR receptor expression patterns at single cell level in NK cells in 17 donors. The function of NK cell subsets is determined by degranulation assays using target cells expressing self, cognate, control or no HLA class I. Donors could be grouped into three groups: their NK cells possess potential for alloreactivity, autoreactivity based on the presence of NK cells expressing particular KIR only (mono-KIR) in the absence of its ligand or lack alloreactivity. All donors possess NK cells lacking all detectable inhibitory receptors. Both potential autoreactive subpopulations did not respond to HLA class I-positive target cells. They retain partial reactivity against HLA class I-negative tumour target cells. Mono-KIR NK cells without the corresponding ligands in the individuals and NK cells lacking all inhibitory receptors behave self-tolerant. Our results suggest alternative mechanisms than HLA-specific inhibitory receptors to control NK cell activity. But HLA seems to be involved in shaping effector function of the NK cell repertoire.
Collapse
Affiliation(s)
- J Hasenkamp
- Department of Haematology & Oncology, Georg-August University of Goettingen, Goettingen, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Gisselbrecht C, Bethge W, Duarte RF, Gianni AM, Glass B, Haioun C, Martinelli G, Nagler A, Pettengell R, Sureda A, Tilly H, Wilson K. Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40:1007-17. [PMID: 17922042 DOI: 10.1038/sj.bmt.1705868] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on (90)Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose (90)Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose (90)Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also (90)Y-ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.
Collapse
Affiliation(s)
- C Gisselbrecht
- Institut d'Hématologie, Hôpital Saint-Louis, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Combs AP, Glass B, Galya LG, Li M. Asymmetric Synthesis of the (S)-1,1-Dioxido-isothiazolidin-3-one Phosphotyrosine Mimetic via Reduction of a Homochiral (R)-Oxido-isothiazolidin-3-one. Org Lett 2007; 9:1279-82. [PMID: 17338536 DOI: 10.1021/ol0701262] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
[structure: see text]. The first asymmetric synthesis of the (S)-1,1-dioxido-isothiazolidin-3-one ((S)-IZD) pTyr mimetic, which has been incorporated into the recently reported potent protein tyrosine phosphatase 1B (PTP1B) inhibitors, is presented herein. The key reaction is the reduction of the (R)-oxido-isothiazolidin-3-one heterocycle with excellent regiochemical and stereochemical control (>98% ee; 82% yield).
Collapse
Affiliation(s)
- Andrew P Combs
- Discovery Chemistry, Experimental Station, Incyte Corporation, Wilmington, DE 19880, USA.
| | | | | | | |
Collapse
|
42
|
Ala PJ, Gonneville L, Hillman M, Becker-Pasha M, Yue EW, Douty B, Wayland B, Polam P, Crawley ML, McLaughlin E, Sparks RB, Glass B, Takvorian A, Combs AP, Burn TC, Hollis GF, Wynn R. Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B. J Biol Chem 2006; 281:38013-21. [PMID: 17028182 DOI: 10.1074/jbc.m607913200] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Structural analyses of the protein-tyrosine phosphatase 1B (PTP1B) active site and inhibitor complexes have aided in optimization of a peptide inhibitor containing the novel (S)-isothiazolidinone (IZD) phosphonate mimetic. Potency and permeability were simultaneously improved by replacing the polar peptidic backbone of the inhibitor with nonpeptidic moieties. The C-terminal primary amide was replaced with a benzimidazole ring, which hydrogen bonds to the carboxylate of Asp(48), and the N terminus of the peptide was replaced with an aryl sulfonamide, which hydrogen bonds to Asp(48) and the backbone NH of Arg(47) via a water molecule. Although both substituents retain the favorable hydrogen bonding network of the peptide scaffold, their aryl rings interact weakly with the protein. The aryl ring of benzimidazole is partially solvent exposed and only participates in van der Waals interactions with Phe(182) of the flap. The aryl ring of aryl sulfonamide adopts an unexpected conformation and only participates in intramolecular pi-stacking interactions with the benzimidazole ring. These results explain the flat SAR for substitutions on both rings and the reason why unsubstituted moieties were selected as candidates. Finally, substituents ortho to the IZD heterocycle on the aryl ring of the IZD-phenyl moiety bind in a small narrow site adjacent to the primary phosphate binding pocket. The crystal structure of an o-chloro derivative reveals that chlorine interacts extensively with residues in the small site. The structural insights that have led to the discovery of potent benzimidazole aryl sulfonamide o-substituted derivatives are discussed in detail.
Collapse
Affiliation(s)
- Paul J Ala
- Incyte Corporation, Wilmington, Delaware 19880, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Schiel X, Link H, Maschmeyer G, Glass B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann H, Hentrich M. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 2006; 34:118-26. [PMID: 16804654 DOI: 10.1007/s15010-006-5113-9] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2005] [Accepted: 03/08/2006] [Indexed: 11/29/2022]
Abstract
BACKGROUND The aim of the study was to compare the efficacy of empirical antifungals in combination with broad spectrum antibiotics with that of antibiotics alone in high risk febrile neutropenic cancer patients not responding to initial antibacterial therapy. PATIENTS AND METHODS A prospective, randomized controlled trial was conducted at 22 cancer centers in Germany. Patients with fever of unknown origin were randomized to either piperacillin (Pip) plus an aminoglycoside (AMG) (arm A) or a third generation cephalosporin (Ceph) plus AMG (arm B). Patients not responding after 4-6 days were randomized to either imipenem (Imi) plus glycopeptide (GLP) (arm C), or Imi/GLP plus amphotericin B deoxycholate (AmB) plus 5-flucytosine (5-FC) (arm D), or Imi/GLP plus fluconazole (Fluco) (arm E). A successful outcome was defined as resolution of fever. RESULTS In arm A, 192 of 373 patients (51.5%) responded as compared to 176 of 344 patients (51.2%) in arm B. The response rates of 155 patients randomized for further empirical treatment were 55.6%, 77.8% and 62.5% in arm C, D and E, respectively. The difference between arm C and D was of borderline statistical significance (p = 0.06) after correction for multiple testing. CONCLUSION In neutropenic cancer patients with persistent fever the combination of antibiotics with AmB/5-FC is superior to salvage antibacterial therapy alone. There is no difference in efficacy between Pip and third generation Ceph given as initial empirical therapy in combination with an AMG.
Collapse
Affiliation(s)
- X Schiel
- Dept. of Internal Medicine III, Ludwig Maximillian University-Grosshadern, Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Basecke J, Karim K, Podleschny M, Becker A, Glass B, Trumper L, Griesinger F. MLL rearrangements emerge during spontaneous apoptosis of clinical blood samples. Leukemia 2006; 20:1193-4. [PMID: 16572197 DOI: 10.1038/sj.leu.2404211] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
45
|
Hasenkamp J, Borgerding A, Wulf G, Uhrberg M, Jung W, Dingeldein S, Truemper L, Glass B. Resistance Against Natural Killer Cell Cytotoxicity: Analysis of Mechanisms. Scand J Immunol 2006; 64:444-9. [PMID: 16970688 DOI: 10.1111/j.1365-3083.2006.01803.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Target cell resistance against natural killer (NK) cell-mediated cytotoxicity obstructs NK cell-based immunotherapy of leukaemia. Several mechanisms of resistance have been described. Because of lack of simple assays for analysing these mechanisms, their relative impact on a given effector-target pair is mostly unknown. We here analysed the combination of the Granzyme B (GrB) enzyme-linked immunospot assay (ELISPOT) for the assessment of NK cell reactivity and cytotoxicity assays to estimate target cell escape mechanisms. Target cell recognition failure leads to negative GrB ELISPOT results, whereas target cell resistance shows positive GrB ELISPOT results in the absence of cytotoxicity. We confronted NK cells with the sensitive target cell line K562, and with the resistant cell lines ML2, SupB15 and Raji. ML2 cells sufficiently activated GrB-release whilst being resistant against cytotoxic granules of NK cells. Partial resistance of Raji results from the interaction of HLA class I with inhibitory killer immunglobulin-like receptors (KIR) on the NK cells. Failure of target recognition by HLA class I-KIR interaction, lacking ligands to stimulatory NK cell receptors and partial resistance to cytotoxic granules all contributed to resistance of SupB15. In conclusion, revealing the mechanisms of resistance against NK cell-mediated cytotoxicity may allow improving the results of NK-based immunotherapy.
Collapse
MESH Headings
- Cell Line, Tumor
- Clone Cells
- Cytotoxicity Tests, Immunologic/methods
- Cytotoxicity, Immunologic
- Granzymes
- HLA-A3 Antigen/biosynthesis
- HLA-A3 Antigen/genetics
- HLA-A3 Antigen/metabolism
- Humans
- Immunity, Innate/genetics
- K562 Cells
- Killer Cells, Natural/enzymology
- Killer Cells, Natural/immunology
- Killer Cells, Natural/metabolism
- Leukemia/enzymology
- Leukemia/immunology
- Leukemia/pathology
- Receptors, Immunologic/biosynthesis
- Receptors, Immunologic/genetics
- Receptors, Immunologic/metabolism
- Receptors, KIR
- Serine Endopeptidases/analysis
Collapse
Affiliation(s)
- J Hasenkamp
- Department of Haematology and Oncology, Georg-August University of Goettingen, Goettingen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Hohloch K, Wulf G, Jung W, Stitz E, Meller J, Glass B, Truemper L, Griesinger F. Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Results of a phase II study of the German RAIT Study Group. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13007 Background: Radioimmunotherapy has been shown to be effective in CD20 + B-cell lymphomas. Both non-myeloablative as well as myeloablative regimens have been employed for low grade and high grade lymphomas with impressive response rates and remission durations. Recently, the Press group and our group published data on myeloablative 131-I-anti-CD20 RAIT with high response rates and favourable long term survival especially in follicular lymphomas and transformed FL. Therefore, a phase II study is currently being done within the German Radioimmunotherapy Group, interim analysis data are presented. Methods: Patients were to receive R-Dexa-BEAM, followed by BEAM and HD-RAIT 2–6 months after BEAM. 131-I-Rituximab was administered with a maximum kidney and lung dose of 25 Gy. Sample size was calculated to be 16 to evaluate toxicity and feasibility of the tandem approach as primary endpoint. Results: 16 pts with relapsed (14) or primary refractory (2) B-cell lymphomas (FLI,II: 4pts; DLBCL: 4pts (all early relapses); transformed FL: 6 pts; MCL:1 pt, marginal zone lymphoma: 1 pt) were treated with 1 (15 pts) or 2 cycles (1 pt) of R-Dexa-BEAM. 13/16 pts achieving PR (5) or CRu (8) were treated with BEAM, 2 pts with PD and 1 with subdural hematoma were drop outs. After BEAM, 9/13 pts were in CR, 3/13 PR, 1/13 PD. Of 12 responding pts, 6 received HD-RAIT (1 pancytopenia, 1 hepatic, 2 pulmonary toxicity, 3 too early). After HD RAIT, 5/6 pts were in CR, 1 in PR. 4/6 pts (3 CR, 1 PR) are alive for 22–31 months, 2 pts died in CR, 1 of interstitial lung disease 2 months after HD-RAIT, 1 pt of pneumonia 8 months after HD-RAIT. Conclusions: Myeloablative RAIT is a feasible and effective treatment modality for relapsed poor prognosis CD20+ B-NHL not having severe toxicity due to the salvage regimen and HD-chemotherapy. HD RAIT offers the potential for long term relapse free survival. Final analysis of toxicity and outcome of this phase II study will be presented at the meeting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Hohloch
- University of Goettingen, Goettingen, Germany
| | - G. Wulf
- University of Goettingen, Goettingen, Germany
| | - W. Jung
- University of Goettingen, Goettingen, Germany
| | - E. Stitz
- University of Goettingen, Goettingen, Germany
| | - J. Meller
- University of Goettingen, Goettingen, Germany
| | - B. Glass
- University of Goettingen, Goettingen, Germany
| | - L. Truemper
- University of Goettingen, Goettingen, Germany
| | | |
Collapse
|
47
|
Glass B, Plaine HL. The Role of Oxygen Concentration in Determining the Effectiveness of X-Rays on the Action of a Specific Gene in Drosophila Melanogaster. Proc Natl Acad Sci U S A 2006; 38:697-705. [PMID: 16589164 PMCID: PMC1063637 DOI: 10.1073/pnas.38.8.697] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- B Glass
- Department of Biology, The Johns Hopkins University
| | | |
Collapse
|
48
|
Combs AP, Zhu W, Crawley ML, Glass B, Polam P, Sparks RB, Modi D, Takvorian A, McLaughlin E, Yue EW, Wasserman Z, Bower M, Wei M, Rupar M, Ala PJ, Reid BM, Ellis D, Gonneville L, Emm T, Taylor N, Yeleswaram S, Li Y, Wynn R, Burn TC, Hollis G, Liu PCC, Metcalf B. Potent Benzimidazole Sulfonamide Protein Tyrosine Phosphatase 1B Inhibitors Containing the Heterocyclic (S)-Isothiazolidinone Phosphotyrosine Mimetic. J Med Chem 2006; 49:3774-89. [PMID: 16789735 DOI: 10.1021/jm0600904] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Potent nonpeptidic benzimidazole sulfonamide inhibitors of protein tyrosine phosphatase 1B (PTP1B) were derived from the optimization of a tripeptide containing the novel (S)-isothiazolidinone ((S)-IZD) phosphotyrosine (pTyr) mimetic. An X-ray cocrystal structure of inhibitor 46/PTP1B at 1.8 A resolution demonstrated that the benzimidazole sulfonamides form a bidentate H bond to Asp48 as designed, although the aryl group of the sulfonamide unexpectedly interacts intramolecularly in a pi-stacking manner with the benzimidazole. The ortho substitution to the (S)-IZD on the aryl ring afforded low nanomolar enzyme inhibitors of PTP1B that also displayed low caco-2 permeability and cellular activity in an insulin receptor (IR) phosphorylation assay and an Akt phosphorylation assay. The design, synthesis, and SAR of this novel series of benzimidazole sulfonamide containing (S)-IZD inhibitors of PTP1B are presented herein.
Collapse
Affiliation(s)
- Andrew P Combs
- Incyte Corporation, Discovery Chemistry, Applied Technology, and Drug Metabolism, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O, Sandrock D, Munz DL, Glass B, Thiel E, Blau IW. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006; 47:59-63. [PMID: 16321828 DOI: 10.1080/10428190500260478] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Radioimmunotherapy (RIT) of relapsed lymphoma is gaining increasing importance. Especially the commercially available anti-CD20 antibody 90Y-ibritumomab tiuxetan is currently under investigation in various trials including dose escalation and autologous hematopoietic progenitor cell support. It is not clear, however, whether the implementation of this radiolabeled antibody into another treatment option for relapsed or poor risk lymphoma patients-allogeneic hematopoietic cell transplantation-interferes with or delays successful engraftment. This study reports encouraging results with 2 relapsed lymphoma patients (1 transformed marginal zone lymphoma and 1 mantle cell lymphoma) who underwent allogeneic hematopoietic cell transplantation from HLA-matched donors. The conditioning regimen consisted of Rituximab 250 mg m(-2) on days -21 and -14, 0.4 mCi kg(-1) body weight 90Y-ibritumomab tiuxetan on day -14 and fludarabine (30 mg m(-2)) plus cyclophosphamide (500 mg m(-2)) on days -7 to -3. The data demonstrate that engraftment is fast and reliable with leukocytes >1 x 10(9) L(-1) on day 12 and platelets >50 x 10(9) L(-1) on day 10. Thus, the incorporation of radioimmunotherapy into allogeneic transplant protocols combines established modalities with proven anti-lymphoma activity and, hence, offers an attractive new therapeutic option for relapsed lymphoma patients.
Collapse
Affiliation(s)
- T Fietz
- Department of Hematology, Oncology and Transfusion Medicine, Charité-Campus Benjamin Franklin, Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Zeis M, Uharek L, Hartung G, Glass B, Steinmann J, Schmitz N. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice. Hematol J 2005; 2:136-44. [PMID: 11424006 DOI: 10.1038/sj/thj/6200087] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 05/25/2000] [Accepted: 06/30/2000] [Indexed: 11/08/2022]
Abstract
INTRODUCTION The transfer of allogeneic lymphocytes contained in a hematopoietic stem cell graft confers an immune-mediated antileukemic effect, termed the graft-vs-leukemia (GVL) effect. Graft-vs-host disease (GVHD), the most detrimental complication of allogeneic BMT, largely resides within the same lymphocyte population. Therefore, separation of GVL- and GVH-reactions is a long-standing goal of experimental studies dealing with allogeneic transplantation of hematopoietic stem cells. MATERIALS AND METHODS The objective of the current study was to assess the potential of Th1- and Th2-type CD4+ T cells in mediating GVHD and GVL effects in a fully allogeneic murine transplant model. BALB/c (H-2d) mice were given a dose of A20 (H-2d, B-cell leukemia) cells two days prior to lethal total body irradiation (TBI) and transplantation of fully mismatched (C57BL/6, H-2b) T-cell depleted (anti-Thy1.2, CD90) bone marrow (TCD-BM) cells. Graded numbers of either unmanipulated, Th1- or Th2-polarized highly enriched CD4+ donor type T cells (10(6) or 10(7)) were administered 2 h posttransplant. Infusion of 10(6) of unmanipulated, Th1-, or Th2-primed CD4+ T cells resulted in moderate GVHD-related mortality (40%, 50%, 10%) and significantly improved long-term survival (50%, 45%, 46% surviving the observation period of 120 days) as compared to animals receiving TCD-BM alone (18%). RESULTS The administration of 10(7) unmanipulated or Th1-type CD4+ T cells given shortly after transplantation led to death of all mice within 50 days due to fatal acute GVHD. In contrast, the adoptive transfer of 10(7) Th2-primed CD4+ T cells resulted in significant improvement of long-term survival (80%) compared to the TCD-BM group. This powerful GVL effect was associated with a substantially lower incidence of lethal acute GVHD (10%) if compared to the results of transplantation of Th1-type CD4+ T cells. CONCLUSION These results demonstrate that allogeneic Th2-type CD4+ T cells given post BMT can induce GVL effects in a cell-dose-dependent manner without increasing the risk of severe acute GVHD.
Collapse
Affiliation(s)
- M Zeis
- 2nd Department of Internal Medicine, University of Kiel, Kiel, Germany.
| | | | | | | | | | | |
Collapse
|